Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
US-2024130341-A1 · Apr 25, 2024 · US
US11825817B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11825817-B2 |
| Application number | US-201716337381-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 28, 2017 |
| Priority date | Sep 28, 2016 |
| Publication date | Nov 28, 2023 |
| Grant date | Nov 28, 2023 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
In this application, the provided are: a Down syndrome rat model characterized in that a rat gene homologous to at least one gene present on a human chromosome 21 or fragment thereof is a trisomy and is transmittable to progeny; or a Down syndrome rat model characterized in that it comprises a human chromosome 21 or fragment thereof, or an exogenous rat chromosome or fragment thereof on which a rat gene homologous to the human chromosome 21 or fragment thereof is present, wherein at least one gene on the human chromosome 21 or fragment thereof or on the exogenous rat chromosome or fragment thereof is added to endogenous rat genes homologous to the at least gene so as to become a trisomy and to be transmittable to progeny: and a method for producing the Down syndrome rat model.
Opening claim text (preview).
The invention claimed is: 1. A genetically modified rat that models Down Syndrome, wherein at least 80% of tissues in the rat comprise a full length human chromosome 21, and the rat exhibits symptoms of Down Syndrome. 2. The genetically modified rat that models Down Syndrome of claim 1 , wherein the human chromosome 21 comprises DNA encoding a fluorescent protein. 3. A method for producing a genetically modified rat that models Down syndrome, the method comprising: a) fusing a microcell comprising a full-length human chromosome 21 with a male embryonic stem (ES) cell such that a chimeric ES cell comprising the full-length human chromosome 21 is obtained; b) introducing the chimeric ES cells obtained in step a) into a rat blastocyst or 8-cell embryo such that a chimeric embryo is obtained, c) transplanting the chimeric embryo obtained in step b) into a recipient female rat such that a chimeric male rat is obtained; d) inseminating a female rat with spermatids obtained from the chimeric male rat to produce a plurality of rat progeny; and e) selecting the genetically modified rat of claim 2 from the plurality of rat progeny produced in step (d). 4. The method according to claim 3 , wherein the human chromosome 21 comprises DNA encoding a fluorescent protein.
Chimeric vertebrates, e.g. comprising exogenous cells · CPC title
Knock-in vertebrates, e.g. humanised vertebrates · CPC title
Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion {(monoclonal antibodies C07K16/00; apparatus for cell fusion C12M)} · CPC title
Animals modified by administration of exogenous cells · CPC title
Humanized animals · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.